Clinical Trial Update: S 81694 Plus Paclitaxel in Metastatic Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for S 81694 combined with Paclitaxel in metastatic breast cancer and metastatic triple-negative breast cancer, completed Phases 1 and 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• S 81694

Snippet

Sponsor: Institut de Recherches Internationales Servier | Conditions: Metastatic Breast Cancer, Metastatic Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED